Handelsavisen
prelaunch
HC
HCAT.O NASDAQ Software

Health Catalyst Inc

$2,31
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
170,1M USD
P/E
EV / Rev
0,4x
Div yield
Op margin
-30,5 %
ROE
-5,8 %
Net margin
-27,6 %
Debt / equity
0,64
Beta
52w range
Volume
Day range
Prev close
$1,30
Open
$1,27
Next earnings
2026-07-28
Ex-dividend
TR 1Y
About

Health Catalyst Inc provides data and analytics solutions to healthcare organizations to improve clinical, financial, and operational outcomes.

Business. Health Catalyst Inc (HCAT.O) is a software company operating within the Technology sector, specifically focused on Software & IT Services. The firm generates revenue through a subscription model, with key performance indicators including annual recurring revenue and net revenue retention. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level. Health Catalyst is listed under the ticker HCAT.O.

Classification92 %
SectorTechnology
Business sectorSoftware & IT Services
IndustrySoftware
Generated · model-assisted
Sell-side consensus
HOLD9 analysts
2 buy7 hold0 sell
Avg 12m price target1,96

Analyst recommendations

9 analysts · consensus Hold
Buy2
Hold7
Sell0
12-month price target
1,96
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
See all catalysts →

At a glance

Score
61
composite score
Valuation
valuation pending
Analysts
Hold
9 analysts · indicative
Ownership
Nuveen LLC
largest disclosed fund holder
Profitability
-5,8 %
return on equity
Quality
60
quality score (0-100)

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning HCAT.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,2 %+1,6 %+2,4 %
    Energy+1,2 %+5,3 %+1,4 %
    Real Estate+0,7 %+4,1 %+0,8 %
    Health Care+0,6 %−0,5 %+0,8 %
    Consumer Discretionary+0,3 %+8,7 %+0,5 %
    Information Technology · THIS SECTOR−0,3 %+6,5 %−0,1 %
    Financials−0,3 %−4,5 %−0,1 %
    Consumer Staples−1,0 %+3,0 %−0,8 %
    Utilities−1,5 %−21,2 %−1,3 %
    Industrials−1,7 %−2,3 %−1,6 %
    Communication Services

    Developing storylines

    No tracked sagas currently linked to HCAT.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-07-07 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
    • Peers
    • EarningsQ2 2026 earnings (expected)2026-07-28 · estimated · ServiceNow (NOW)
    • EarningsQ2 2026 earnings (expected)2026-08-28 · estimated · Salesforce (CRM)
    • Macro
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
    • Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
    • Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
    • Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Composite score61 / 100
    Composite score 0-100 · Data quality 0,60
    Data quality0,60 / 1.00

    Synthesis

    Business

    Health Catalyst Inc (HCAT.O) is a software company operating within the Technology sector, specifically focused on Software & IT Services. The firm generates revenue through a subscription model, with key performance indicators including annual recurring revenue and net revenue retention. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level. Health Catalyst is listed under the ticker HCAT.O.

    Classification92 %
    SectorTechnology
    Business sectorSoftware & IT Services
    IndustrySoftware
    AI synthesis
    GENERATED

    Health Catalyst operates with a market capitalization of $86.1 million and a price-to-book ratio of 0.24, indicating a significant discount to its book value. The company holds $201.4 million in cash and equivalents but carries $228.4 million in long-term debt, resulting in a net cash position of -$27.0 million. This negative net cash position raises liquidity concerns despite a current ratio of 4.31, which suggests the company can cover its short-term liabilities multiple times over.

    Profitability metrics show Health Catalyst is currently unprofitable, with a net loss of $20.6 million and an operating loss of $22.8 million. The company's return on equity is -5.76%, and its return on assets is -2.96%, both significantly below the industry median for software firms. Gross profit of $36.6 million represents 49.0% of revenue, which is in line with the industry average for health care technology firms.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to sector-specific risks, particularly in the healthcare technology space. The company's operating cash flow of $10.3 million is positive, but its free cash flow is negative at -$12.8 million, indicating that capital expenditures are outpacing operating cash flow.

    Looking ahead, Health Catalyst is expected to see a modest improvement in revenue, with a projected growth rate of 2.5% for the current fiscal year and 3.0% for the next fiscal year. However, the company's operating losses are expected to persist, with a narrowing of the operating loss margin from -30.5% to -28.0% over the next 12 months. The risk assessment indicates a medium liquidity risk due to the negative net cash position and a low dilution risk, with no near-term pressure from share issuance.

    Recent filings and transcripts highlight ongoing challenges in scaling the business while maintaining profitability. The company has not issued any new shares in the past 12 months, and there are no indications of a near-term capital raise. Analysts have a mixed outlook, with a mean price target of $1.96 and a median of $2.00, suggesting a potential upside of 67.5% from the current market price of $1.17.

    Key takeaways
    • Health Catalyst is trading at a significant discount to book value, with a price-to-book ratio of 0.24.
    • The company is unprofitable, with a net loss of $20.6 million and a return on equity of -5.76%.
    • Despite a strong current ratio of 4.31, the company has a negative net cash position of -$27.0 million.
    • Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
    • Analysts project a potential upside of 67.5% from the current market price, with a mean price target of $1.96.
    • The company is expected to narrow its operating loss margin from -30.5% to -28.0% over the next 12 months.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 2

    Analysts project 18.7% upside to a mean price target of $1.96 from the current $1.65.

    The company maintains a medium leverage band with a debt-to-equity ratio of 0.62.

    BEAR CASE · 2

    The company faces high credit risk according to internal risk flag assessments.

    Return on equity of -5.76% significantly underperforms the software cohort median of 2.8%.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-12
    Q4 2025 · Quarter highlights
    Open report →

    Revenue $74.7M, −6,2% YoY; Operating income −391,9% YoY.

    Revenue$74.7M−6,2 % YoY
    Operating income-$86.1M−391,9 % YoY
    Net income-$91.0M−340,3 % YoY
    Free cash flow-$83.7M−454,2 % YoY
    EPS
    Operating cash flow$731.0k−95,0 % YoY
    Financials
    Income statement
    Revenue$74.7M
    Gross profit$39.4M
    Operating income-$86.1M
    Net income-$91.0M
    Margins
    Gross margin52.7%
    Operating margin-115.3%
    Net margin-121.9%
    FCF margin-112.1%
    Balance sheet
    Total assets$502.6M
    Total liabilities$256.9M
    Total equity$245.8M
    Cash & equivalents$50.8M
    Long-term debt$153.3M
    Cash flow
    Operating cash flow$731.0k
    CapEx-$21.6M
    Free cash flow-$83.7M
    SBC
    P&L flow · revenue → net income
    Revenue $74.7MOperating costs $160.8MTax $4.9MNet income $91.0M
    Highlights
    • Revenue $74.7M, −6,2% YoY
    • Operating income −391,9% YoY
    • Net income −340,3% YoY
    • Free cash flow −454,2% YoY
    • Net margin -121.9%

    Valuation TTM

    Market price
    $2,31
    Market cap
    $86.1M
    Enterprise value
    $113.1M
    P/E
    Non-GAAP P/E
    EV / Revenue
    0.4x
    EV / Op income
    EV / OCF
    11.0x
    P / B
    0.2x
    P / Tangible book
    0.2x
    Tangible book
    $357.2M
    Net cash
    -$27.0M
    Current ratio
    4.3
    Debt / equity
    0.6
    ROA
    -3.0%
    ROE
    -5.8%
    Cash conversion
    -50.0%
    CapEx / revenue
    -3.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYTechnologyIndustryDiversified Software585,0B node revenueMSFT 48,2%ORCL 9,8%ADBE 4,1%SE 3,4%NOW 2,3%WDAY 1,6%PANW 1,6%ROP 1,4%Other 27,8%
    Source: company disclosures · own-taxonomy revenue-covered setHCAT 0,1% · rank #78 of 173

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs HCAT · multiples and returns
    MS
    MSFT
    MICROSOFT CORPORATION
    $388,45
    2,90T USD
    P/E
    32,3x
    vs self
    Div yield
    0,9 %
    vs self
    ROE
    23,6 %
    +29,4 vs self
    OR
    ORCL
    ORACLE CORPORATION
    $188,91
    543,3B USD
    P/E
    180,2x
    vs self
    Div yield
    1,2 %
    vs self
    ROE
    36,1 %
    +41,9 vs self
    AD
    ADBE
    ADOBE INC.
    $219,66
    89,3B USD
    P/E
    27,1x
    vs self
    Div yield
    vs self
    ROE
    31,3 %
    +37,0 vs self
    SE
    SE
    Sea Ltd
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    NO
    NOW
    Servicenow Inc
    $100,03
    104,0B USD
    P/E
    271,7x
    vs self
    Div yield
    vs self
    ROE
    4,0 %
    +9,8 vs self
    WD
    WDAY
    WORKDAY, INC.
    $138,46
    35,2B USD
    P/E
    168,2x
    vs self
    Div yield
    vs self
    ROE
    3,3 %
    +9,1 vs self
    PA
    PANW
    Palo Alto Networks Inc
    $359,50
    291,6B USD
    P/E
    727,5x
    vs self
    Div yield
    vs self
    ROE
    6,2 %
    +12,0 vs self
    RO
    ROP
    Roper Technologies Inc
    $360,11
    36,9B USD
    P/E
    96,6x
    vs self
    Div yield
    1,0 %
    vs self
    ROE
    1,9 %
    +7,6 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 33 %
    EPS
    Consensus EPS
    0,14
    Predicted surprise
    -0,02
    Beat probability
    33 %
    Analysts
    9
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,14
    Revenueno estimateno estimate280,2M USD
    Operating incomeno estimateno estimate-24,4M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-07-07

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution9 analysts
    Strong buy1
    Buy1
    Hold7
    Sell0
    Strong sell0
    12-month price target$1,96 · Median $2,00
    Low $1,00High $3,00
    Operating income · consensus-24,4M USD
    EPS surprise
    +31,7 %
    reported vs consensus · beat
    Revenue surprise
    +11,0 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$1,00
    Mean$1,96
    Median$2,00
    High$3,00
    Spot$2,31
    −15.0 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-30,5 %Bottom quartile
    Net Margin-27,6 %Bottom quartile
    ROE-5,8 %Below median
    Capex / Rev-3,8 %Below median
    D/E0,64Bottom quartile
    Cash Conv-0,50Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Health Catalyst Inc Market data — financials · 2026-05-28
    • Health Catalyst Inc Market data — analyst estimates · 2026-05-28
    • Health Catalyst Inc Market data — ESG · 2026-05-28

    Ownership & reference

    Top holders

    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$4M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$35M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$2M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$11M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$2M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$2M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Ben AlbertPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 2 sellsnet -$201K7 insiders · last 365d
    • Albert BenjaminDirector, CEO · Common StockOther 34 485 @ $1,69$58K · 2026-06-10
    • Landry BenjaminGeneral Counsel · Common StockOther 13 779 @ $1,37$19K · 2026-06-01
    • Larson-Green JulieDirector · Common StockOther 12 710 · 2026-06-01
    • Alger JasonChief Financial Officer · Common StockOther 18 804 @ $1,37$26K · 2026-06-01
    • Albert BenjaminDirector, CEO · Common StockOther 336 @ $1,37$460 · 2026-06-01
    • Llewelyn LindaChief People Officer · Common StockOther 8 519 @ $1,37$12K · 2026-06-01
    • Albert BenjaminDirector, CEO · Common StockOther 310 @ $1,34$417 · 2026-05-01
    • Nelson Steven HDirector · Common StockOther 154 808 · 2026-05-01
    • Albert BenjaminDirector, CEO · Common StockOther 1 124 · 2026-04-29
    • Albert BenjaminDirector, CEO · Common StockOther 70 455 @ $1,85$130K · 2026-03-10
    • Landry BenjaminGeneral Counsel · Common StockOther 20 838 @ $1,66$35K · 2026-03-02
    • Alger JasonChief Financial Officer · Common StockOther 26 970 @ $1,66$45K · 2026-03-02
    • Albert BenjaminDirector, CEO · Common StockOther 4 966 @ $1,66$8K · 2026-03-02
    • Llewelyn LindaChief People Officer · Common StockOther 13 836 @ $1,66$23K · 2026-03-02
    • Larson-Green JulieDirector · Common StockOther 8 361 · 2026-03-01
    • Albert BenjaminDirector, CEO · Common StockOther 13 304 @ $1,75$23K · 2026-02-26
    • Llewelyn LindaChief People Officer · Common StockOther 4 471 @ $1,75$8K · 2026-02-26
    • Landry BenjaminGeneral Counsel · Common StockOther 6 317 @ $1,75$11K · 2026-02-26
    • Alger JasonChief Financial Officer · Common StockOther 7 522 @ $1,75$13K · 2026-02-26
    • Albert BenjaminDirector, CEO · Common StockOther 38 833 · 2026-02-25
    • Albert BenjaminDirector, CEO · Common StockOther 930 000 · 2026-02-25
    • Llewelyn LindaChief People Officer · Common StockOther 191 500 · 2026-02-25
    • Llewelyn LindaChief People Officer · Common StockOther 13 195 · 2026-02-25
    • Landry BenjaminGeneral Counsel · Common StockOther 289 000 · 2026-02-25
    • Landry BenjaminGeneral Counsel · Common StockOther 16 473 · 2026-02-25

    Short positioning

    6.3Mshares short-3.6% vs prior
    1.56days to cover
    21.3%short of daily vol
    230fails-to-deliver
    as of 2026-06-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    HCAT.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob33 %Surprise-0,02Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    HCATMSFTCRMNOWSoftware
    This companyPeerSector

    Evidence & claims

    From filings & derived data
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -14.1%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -130.4%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -95.0%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -156.1%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -59.9%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -121.7%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -121.7%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -79.6%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -40.1%Derived (calculated)
    • Net margin (FY 2025-12-31): -57.2%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 1.05xDerived (calculated)
    • Current ratio (FY 2025-12-31): 1.89xDerived (calculated)
    • Return on assets (FY 2025-12-31): -35.4%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -48.0%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -41.5%Derived (calculated)
    • Return on equity (FY 2025-12-31): -72.4%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -32.7%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 1.5%Derived (calculated)
    • Current assets (annual): USD 169.31MSEC XBRL filing
    • Total assets (annual): USD 502.64MSEC XBRL filing
    • Net income (annual): USD -177.97MSEC XBRL filing
    • R&D expense (annual): USD 49.77MSEC XBRL filing
    • Total operating expenses (annual): USD 312.53MSEC XBRL filing
    • Shareholders' equity (annual): USD 245.78MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-07-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-10 00:00 UTCINSIDER6 insider transactions — 2026-06 · net sell $115k
    2026-06-10INSIDERAlbert Benjamin transacted 34.5k sh — Director, CEO ~$58k
    2026-06-04FILING8-K filing →
    2026-06-03FILINGDEF 14A filing →
    2026-06-01INSIDERLandry Benjamin transacted 13.8k sh — General Counsel ~$19k
    2026-06-01INSIDERLarson-Green Julie transacted 12.7k sh — Director
    2026-06-01INSIDERAlger Jason transacted 18.8k sh — Chief Financial Officer ~$26k
    2026-06-01INSIDERAlbert Benjamin transacted 336 sh — Director, CEO ~$0k
    2026-06-01INSIDERLlewelyn Linda transacted 8.5k sh — Chief People Officer ~$12k
    2026-05-11FILING10-Q filing →
    2026-05-11FILING8-K filing →
    2026-05-01 00:00 UTCINSIDER2 insider transactions — 2026-05
    2026-05-01INSIDERAlbert Benjamin transacted 310 sh — Director, CEO ~$0k
    2026-05-01INSIDERNelson Steven H transacted 154.8k sh — Director
    2026-04-30FILING8-K filing →
    2026-04-29 00:00 UTCINSIDER1 insider transaction — 2026-04
    2026-04-29INSIDERAlbert Benjamin transacted 1.1k sh — Director, CEO
    2026-04-27FILING8-K filing →
    2026-04-03FILING8-K filing →
    2026-03-12 16:11 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 74.7M · Net USD -91.0M
    2026-03-12 16:11 UTCEARNINGSAnnual results — FY 2026 Revenue USD 311.1M · Net USD -178.0M
    2026-03-12FILING10-K filing →
    2026-03-12FILING8-K filing →
    2026-03-10 00:00 UTCINSIDER6 insider transactions — 2026-03 · net sell $241k
    2026-03-10INSIDERAlbert Benjamin transacted 70.5k sh — Director, CEO ~$130k
    2026-03-02INSIDERLandry Benjamin transacted 20.8k sh — General Counsel ~$35k
    2026-03-02INSIDERAlger Jason transacted 27.0k sh — Chief Financial Officer ~$45k
    2026-03-02INSIDERAlbert Benjamin transacted 5.0k sh — Director, CEO ~$8k
    2026-03-02INSIDERLlewelyn Linda transacted 13.8k sh — Chief People Officer ~$23k
    2026-03-01INSIDERLarson-Green Julie transacted 8.4k sh — Director
    2026-02-26 00:00 UTCINSIDER13 insider transactions — 2026-02
    2026-02-26INSIDERAlbert Benjamin transacted 13.3k sh — Director, CEO ~$23k
    2026-02-26INSIDERLlewelyn Linda transacted 4.5k sh — Chief People Officer ~$8k
    Showing the 40 most recent of 63 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-07 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage